{"name":"Medicines for Malaria Venture","slug":"medicines-for-malaria-venture","ticker":"","exchange":"","domain":"mmv.org","description":"Medicines for Malaria Venture (MMV) is a not-for-profit public-private partnership that was established as a foundation in Switzerland in 1999. Its main mission is to reduce malaria in disease-endemic countries by developing and facilitating the delivery of antimalarial drugs.","hq":"Geneva","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Administration of the malaria inoculum","genericName":"Administration of the malaria inoculum","slug":"administration-of-the-malaria-inoculum","indication":"Other","status":"phase_1"},{"name":"MMV390048 formulation A","genericName":"MMV390048 formulation A","slug":"mmv390048-formulation-a","indication":"Other","status":"phase_1"},{"name":"Atoguanil","genericName":"Atoguanil","slug":"atoguanil","indication":"Other","status":"phase_1"},{"name":"DSM265 ymg","genericName":"DSM265 ymg","slug":"dsm265-ymg","indication":"Other","status":"phase_2"},{"name":"Sporozoites","genericName":"Sporozoites","slug":"sporozoites","indication":"Other","status":"phase_1"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"DSM265 xmg","genericName":"DSM265 xmg","slug":"dsm265-xmg","indication":"Malaria","status":"phase_2"},{"name":"Mefloquine plus artesunate","genericName":"Mefloquine plus artesunate","slug":"mefloquine-plus-artesunate","indication":"Uncomplicated Plasmodium falciparum malaria","status":"phase_3"},{"name":"PQP","genericName":"PQP","slug":"pqp","indication":"Malaria prevention and treatment (Plasmodium falciparum and other species)","status":"marketed"},{"name":"Pyronaridine artesunate","genericName":"Pyronaridine artesunate","slug":"pyronaridine-artesunate","indication":"Uncomplicated malaria caused by Plasmodium falciparum","status":"marketed"}]}],"pipeline":[{"name":"Administration of the malaria inoculum","genericName":"Administration of the malaria inoculum","slug":"administration-of-the-malaria-inoculum","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"DSM265 xmg","genericName":"DSM265 xmg","slug":"dsm265-xmg","phase":"phase_2","mechanism":"DSM265 is a dihydroorotate dehydrogenase (DHODH) inhibitor.","indications":["Malaria"],"catalyst":""},{"name":"MMV390048 formulation A","genericName":"MMV390048 formulation A","slug":"mmv390048-formulation-a","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Atoguanil","genericName":"Atoguanil","slug":"atoguanil","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DSM265 ymg","genericName":"DSM265 ymg","slug":"dsm265-ymg","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Mefloquine plus artesunate","genericName":"Mefloquine plus artesunate","slug":"mefloquine-plus-artesunate","phase":"phase_3","mechanism":"This combination uses mefloquine (a quinoline antimalarial) and artesunate (an artemisinin derivative) to kill malaria parasites through complementary mechanisms that reduce drug resistance.","indications":["Uncomplicated Plasmodium falciparum malaria","Malaria in endemic regions with artemisinin resistance"],"catalyst":""},{"name":"PQP","genericName":"PQP","slug":"pqp","phase":"marketed","mechanism":"PQP is a quinolone-based antimalarial that inhibits parasite DNA gyrase and topoisomerase II, disrupting DNA replication in Plasmodium species.","indications":["Malaria prevention and treatment (Plasmodium falciparum and other species)"],"catalyst":""},{"name":"Pyronaridine artesunate","genericName":"Pyronaridine artesunate","slug":"pyronaridine-artesunate","phase":"marketed","mechanism":"Pyronaridine artesunate is a fixed-dose combination antimalarial that kills malaria parasites through dual mechanisms: pyronaridine intercalates into parasite DNA while artesunate generates reactive oxygen species that damage parasite structures.","indications":["Uncomplicated malaria caused by Plasmodium falciparum","Uncomplicated malaria caused by Plasmodium vivax"],"catalyst":""},{"name":"Sporozoites","genericName":"Sporozoites","slug":"sporozoites","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxON3gyWEZJZzVsRkFjYl9hVEp0Ty1CemI0enBxYjh6eGNKaTFOVDBWSlBqX2Y0b04xSjYxYmFyU3JKVERpbkU0Y1hwVEV2RUMycm84Z1lmc1puS01OdUFveXRQMTNYSldYX3JlSjhDRWl1elYtM0xPbExZXzNMaS1VZjJidHJuQzlqS05aUlVhckU?oc=5","date":"2025-11-13","type":"pipeline","source":"pharmaphorum","summary":"Novartis says novel drug could counter malaria resistance - pharmaphorum","headline":"Novartis says novel drug could counter malaria resistance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNb1hMYzdVUFltQi1Zc1R3SXJWTGtCcXRRV0dHRGl3RHJiQTNEQ3UyaWhOTzMxd3gycFhPeDN3ZTBfcTAxSW8taDJkQ19fNzY0MTcwVnl6WmpCM2I3V2J3Ulp2d3VaT3VPX0s4a2YxMXM4dFNscnp2bVBSRnl2aV9iLXd0a2FoaVc0SW50YVA1SXdFcUplS2loM3BhT1RUQUxNZ09fT0liUWVBUkw2TFV2TlFoMmhrU2xu?oc=5","date":"2025-11-13","type":"pipeline","source":"The Pharma Letter","summary":"Novartis’ GanLum could be ‘biggest advance in malaria treatment for decades’ - The Pharma Letter","headline":"Novartis’ GanLum could be ‘biggest advance in malaria treatment for decades’","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxNckdHcEpLenJHeGhzczJlWWVLd0NTU3RTSlZCRlc3OENIdnAwSlJSa3dNMnE3cjNsRTVWejBYejV2NFFSODRlZ2FfcHNJQXZxZC0xNWRmNTBqWXFxcEctT0VNMm9SYURVZFUtZUdWM0ZmbVF0SmZqaVVFSWFJcTFjOWR1SFE3Mktndmp3Zm9rTnhvT2UxSjNPVzR3bTlETXNhM1lFREx3YjN2THBiQVduT3o0VmxRbUF6VW9MdmluZ3hZVkZOUVRldjgyWmc4dTYyNDd6ckZRbHFqcmVRbnQ4TV9VYjNuZXc?oc=5","date":"2025-11-12","type":"pipeline","source":"Reuters","summary":"New, effective anti-malaria drug could help fight rising resistance, says Novartis - Reuters","headline":"New, effective anti-malaria drug could help fight rising resistance, says Novartis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPZnA1NzRndlpFRXNIQzAxbi1SQzY0M29DeGRYMWJsSVJaRV9TTXhRQkI4WWc1TkZFRldmZGZjX2pVOFlTOHJxcVNJNWdhOG1XRkVwUGpYcjBqZ0NKUGtkZllMcUpKMHFyX0ZXT1NvSURjT3NBUWlRUmVTdVpzYjZRVDZqeGpVdDhjd3hfQkFCTkJXQk9wbnhJ?oc=5","date":"2025-07-11","type":"regulatory","source":"drugdiscoverytrends.com","summary":"Swissmedic approves first malaria treatment for infants - drugdiscoverytrends.com","headline":"Swissmedic approves first malaria treatment for infants","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2025-07-09","type":"regulatory","source":"Medical Dialogues","summary":"Breakthrough for babies: Novartis Coartem Baby approved as first Malaria drug for Infants - Medical Dialogues","headline":"Breakthrough for babies: Novartis Coartem Baby approved as first Malaria drug for Infants","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxORm9ZelByVTBRSnk3Q3JxTUU3Y0FIOS1pT3lUNmx0aDN0NTVwY3RLZkxZSldHOTJWQkVPdURSdjBnS2RoMEpDbWF3QlBTbS12MVpwVVhEMzBPQWFZazZQVl9FRVlidmtTNzFSOVM3MUluMTZ2SkdtcWhBMU1lTEFCak1SRmdzVUNCelRGV21YNHktSlhu?oc=5","date":"2025-07-08","type":"regulatory","source":"Fierce Pharma","summary":"Novartis' malaria drug for babies wins world-first approval - Fierce Pharma","headline":"Novartis' malaria drug for babies wins world-first approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9IVnJ0SmxObWt4WTZXdDU0bEl5MWJ0bGZ5OUdSWHN3TDVhRXJzelRGSURfbldlYU5OVmo1eE1kcTFteFRaY1RLRDVHMmJwcEtNVDdN?oc=5","date":"2025-07-08","type":"regulatory","source":"FirstWord Pharma","summary":"Novartis gains first approval of malaria treatment for babies - FirstWord Pharma","headline":"Novartis gains first approval of malaria treatment for babies","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNeVV1Qm1UcHdjbTJiRzc2NUJqb21ndTN5T3hjdVZ4N3k0UlNoQ2FmM2lWSXB6ZTU5eGIwTDBxaGVWQkhSYW5ZQTdDZmFaR2xIZ3MxeENxb291RDBHSVhQX2c1YjY5LWEtRXFhV3o1dmNzYWNRNXNBRFB6V3VXdThlc1hNR0VxSHpMWGZmbk9lUGxyRERtc2dYLVl6OXRDeDh5VWJVQ0hFRU51X2pUOHdkM2RQWU1QTXVKbFVXTk9YVXVDSlQ4eW9mSQ?oc=5","date":"2025-07-08","type":"regulatory","source":"Reuters","summary":"Novartis wins approval for first malaria drug for newborns and babies - Reuters","headline":"Novartis wins approval for first malaria drug for newborns and babies","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPZEpPcmQ4SmEyTF9uWm1sZzlIYU42RUJqLXpFX0dRd2tmRmt2VWhkUE5DREVuY1VEVzc4Z3JXc3AyQmZnUVhSMUd2bnlsN3pHUVpadm95UGVXU0tkZ1ladHQzdTlJX0JFYWFIOXBkbzB5bmx2LWFHOHRIazlJRVkxMVQwbExTRlZRenZB?oc=5","date":"2025-07-08","type":"pipeline","source":"pharmaphorum","summary":"First malaria drug for newborns and young infants cleared - pharmaphorum","headline":"First malaria drug for newborns and young infants cleared","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNR3FzOC1LemhvaXozMDBjdm1pcUs2ZDVwdGIwSV9TMWlpTy1rVXRTcHhUcVFSRXc1OUcxRnUxU0h0bG16Um9ZVjdxeGkyS3pBcHVydWtkQU00TlBaRUt0M2k3eWZHVjJSakVPNlU1LV9wUlpqcEZfYzdvaGk5Wl9KR0FVbVE5WFVSd2xGaFU2X2FFUE16cl8wMmNaRWxOYmE2NDBQRFFHWURZdHVlT2VORHlxblh3S05BNDZV?oc=5","date":"2024-12-10","type":"deal","source":"Health Policy Watch","summary":"African Research Partners Consolidate Network To Accelerate Continental Drug Discovery - Health Policy Watch","headline":"African Research Partners Consolidate Network To Accelerate Continental Drug Discovery","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQb0ZoV2JMTVNlTlFrWjVETkpLNTJGekhSZWhRVWpKZTZJR2hjRDNET1cxMmo0UUdWNkxva0pKSXVuYmJyQTNoYXZWRUo2OEV2XzY1QXdzUXhrZy1Pbk4wZlE0Z2V3cnZfejU5MFJiS1pzdENOZjlvQ244WHh3eDVCNEViYXJEa3ljcnV0VUZzSVUyaGFMeGlIMVRFTEVqWFpnalQxZ2JRb3ZqbkQ1dzg3MDRR?oc=5","date":"2023-12-14","type":"trial","source":"Clinical Trials Arena","summary":"Fosun Pharma secures $3.5m to accelerate development of malaria therapy - Clinical Trials Arena","headline":"Fosun Pharma secures $3.5m to accelerate development of malaria therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPOVJEMWxXa19BY2lScmlLLXBwd05fZTFMeVY5ZjVwSE5sZ1VfR3BEVzd6ZU1YbmRZVWxTOGo1S2M3aHlEXzMzOVhUZ1JVOExUdTVELVpMQzdudjNJZEh3TlJZNHA4LVlCbkxmckMwQ0FKamRlXzdKb0VxdTNZUHIwTHFoaWJnREY2UEdTWXBn?oc=5","date":"2022-11-23","type":"pipeline","source":"BioPharma Dive","summary":"Novartis, research group to advance new kind of malaria drug into late-stage test - BioPharma Dive","headline":"Novartis, research group to advance new kind of malaria drug into late-stage test","sentiment":"neutral"}],"patents":[],"drugCount":9,"phaseCounts":{"phase_1":4,"phase_2":2,"phase_3":1,"marketed":2},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}